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In this issue of Cell Stem Cell, Heidel et al. (2012) use genetic and pharmacological approaches to reveal that
Wnt/b-catenin signaling is required for leukemic stem cell (LSC) maintenance in chronic myeloid leukemia.
They demonstrate that b-catenin inactivation targets imanitib-resistant LSCs in vivo.Chronic myeloid leukemia (CML) is a
stem-cell-derived disorder characterized
by clonal expansion of terminally differen-
tiated myeloid cells. CML presents as a
chronic myeloid neoplasm, most com-
monly progressing from a chronic phase
(CP) through an accelerated phase to a
myeloid/lymphoid blast crisis. The dis-
covery of a constitutively active BCR-
ABL tyrosine kinase, which is generated
from the reciprocal translocation of chro-
mosomes 9 and 22 (de Klein et al.,
1982), as the causative lesion in CML led
to the development of the first tyrosine
kinase inhibitor (TKI) for targeted therapy
of human malignancies: imatinib (Druker
et al., 2001). The dramatic clinical success
of imatinib and of second generation ABL
kinase inhibitors has profoundly changed
the outcome for patients with CML.
Imatinib has emerged as the standard of
care treatment for patients newly diag-
nosed with CP-CML with an 8 year overall
survival of 85%–93%. However, despite
the unprecedented clinical efficacy of
imatinib, several problems remain. The
occurrence of mutations, which render
transformed cells resistant to imatinib,
the modest activity of the inhibitor in
myeloid/lymphoid blast crisis, and drug
intolerance has led to the preclinical and
clinical development of alternate thera-
pies for CML. While second and third
generation inhibitors can effectively sup-
press the disease of patients in CP with
a subset of imatinib resistance alleles,
resistance and/or progression to blast
crisis remain treatment challenges in the
clinical setting (Weisberg et al., 2007).
Likewise, given that cessation and inter-
ruption of TKI therapy leads to clinical
relapse in the majority of patients who
had been in complete remission on TKItherapy for several years, continuous
therapy with TKI is required to prevent
clinical relapse or progression without
offering the potential for cure. Therefore,
intensive efforts are underway to unravel
the underlying mechanisms of this phe-
nomenon and to develop new strategies
to defeat persistent residual CML in the
clinical setting. Here, Heidel and col-
leagues propose that inhibition of Wnt/
b-catenin signaling with the nonsteroidal
inflammatory agent indomethacin rep-
resents a novel, clinically tractable ap-
proach to inhibit CML stem cells in vivo.
While both BCR-ABL-dependent
and -independent mechanisms have
been posited to date for persistence of
CML cells in the setting of BCR-ABL inhi-
bition, recent studies have suggested
that a rare fraction of cells, specifically
leukemic stem cells (LSC), exist within
the bulk population, are inherently TKI
refractory, and serve as a source of these
relapses. In this issue of Cell Stem Cell,
Heidel et al. (2012) take advantage of
genetic and pharmaceutical approaches
to study the role of b-catenin in the main-
tenance of CML LSCs and to evaluate
b-catenin inhibition as a novel therapeutic
strategy for patients with minimal residual
CML disease.
A growing body of evidence has impli-
cated aberrant Wnt/b-catenin signaling
in the genesis of various cancers and
has also linked the canonical Wnt/b-cate-
nin signaling axis with LSC activity (Wang
et al., 2010; Zhao et al., 2007). The study
led by Armstrong and colleagues ad-
dresses for the first time the significance
of Wnt/b-catenin signaling in CML LSC
biology. b-catenin represents the central
downstream effector of the canonical
Wnt signaling pathway. Previous studiesCell Stem Cehave shown that genetic inactivation of
the b-catenin gene, Ctnnb1, impairs the
development of BCR-ABL-induced CML
(Hu et al., 2009; Zhao et al., 2007), but it
had not been demonstrated whether
b-catenin signaling is required to maintain
CML LSCs or whether b-catenin inhibition
could synergize with BCR-ABL inhibition
in vivo to target CML LSCs. To address
those outstanding questions, the authors
ectopically expressed BCR-ABL in bone
marrow (BM) cells harvested from
Ctnnb1;Esr-cre or Ctnnb1;Mx1-cre mice
and subsequently transplanted the BCR-
ABL transduced cells into wild-type recip-
ients. Enforced expression of BCR-ABL in
the hematopoietic mouse system is a reli-
able approach to model human CML in
mice. The usage of conditional loss-of-
function mouse models of b-catenin as
donors in their BM transplantation exper-
iments allowed the authors to genetically
delete b-catenin at defined time points
by administration of tamoxifen or pIpC.
Interestingly, Heidel and colleagues found
that conditional deletion of b-catenin after
CML onset does not affect disease
latency in primary recipients. Neverthe-
less, genetic inactivation of b-catenin sig-
naling in BCR-ABL-positive cells altered
the number of cells with LSC markers
(GFP+Sca-1+) in the BM and peripheral
blood, consistent with LSC-targeted
effects. This finding led the authors to
hypothesize that b-catenin signaling is
required for LSC maintenance, but is
dispensable for the propagation of the
bulk population. Given that imatinib
inhibits bulk leukemic cells, but does not
affect CML LSC survival, the authors
investigated whether b-catenin function
synergizes with imatinib in vivo. In line
with an LSC-targeted effect, they foundll 10, April 6, 2012 ª2012 Elsevier Inc. 351
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Figure 1. Treatment Landscape for CML Patients
The figure denotes current and novel therapeutic options for CML patients. Imatinib therapy reduces
leukemia bulk cells, but does not deplete leukemia stem cells (LSCs). By contrast, inhibition of Wnt
signaling inhibits LSCs but not bulk leukemia cells. For patients with resistance alleles, second generation
TKIs lead to responses, but again do not eradicate LSCs. By contrast, combined TKI treatment and Wnt
pathway inhibition leads to inhibition of LSCs and bulk leukemic cells and to potential eradication of the
CML clone.
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In Translationthat combining TKI treatment with loss of
b-catenin activity through genetic deletion
reduced white blood cell counts and
resulted in a 100-fold decrease in GFP+
and GFP+/lineage-negative cells in the
BM of leukemic mice. Moreover, the
authors showed through serial transplan-
tation of LSC-enriched GFP+Sca-1+ cells
that b-catenin deficiency reduces the
transplantability of CML in untreated
tertiary recipients. These data confirmed
that b-catenin inhibition reduces LSC
frequency through abrogation of their
self-renewal capacity. In a clinically rele-
vant finding, the authors further demon-
strated that pharmacological inhibition of
b-catenin using the COX2-inhibitor indo-
methacin potentiates the therapeutic
benefit of imatinib in vivo. Mice concomi-
tantly treated with both drugs had sig-
nificantly lower numbers of GFP+LSK
cells compared with imanitib only con-
trols, and dual pharmacologic treatment352 Cell Stem Cell 10, April 6, 2012 ª2012 Elof secondary transplant recipients with
indomethacin and imatinib diminished
the disease burden and tertiary trans-
plantability compared with recipients of
imatinib-treated BM. In parallel, the
authors also used ApcMin mice, which
are characterized by enhanced canonical
Wnt signaling, as BM donors to assess
the effects of enhanced Wnt signaling on
CML in vivo in their transplantation
models. However, enhanced Wnt sig-
naling had no significant effect on either
disease burden or LSC numbers. Overall,
these results are clinically relevant
because they provide support that b-cat-
enin could serve as a new LSC target in
persistent CML. Most importantly, they
also investigated the effects of prosta-
glandin signaling, which potentiates Wnt
signaling and is inhibited by indometh-
acin, in primary CML samples. This re-
vealed that reduced prostaglandin levels
was associated with increased clinicalsevier Inc.response to imatinib, consistent with
the hypothesis that there is an inverse
relationship between the level of Wnt
signaling and response to BCR-ABL
inhibition in human CML (Figure 1).
While these findings are interesting,
inhibition of b-catenin signaling is not the
first proposed strategy to target LSCs in
CML. Different groups have shown that
targeting autophagy or Sirt1 can inhibit
CML LSCs, and that histone deacetylase
inhibitors sensitize CML LSCs to imatinib
treatment (Bellodi et al., 2009; Li et al.,
2012; Zhang et al., 2010). Regardless of
the specific approach, these studies in
aggregate emphasize the necessity to
combine LSC-targeting strategies with
TKI to optimize antileukemic therapy. It
is likely that additional LSC targets will
emerge in CML and in other leukemia
disease models in the near future, and
that clinical studies will begin to test these
approaches in patients with hematologic
malignancies. However, there are impor-
tant challenges regarding the ability to
translate these findings into clinical gain,
including prioritization of targets, clinical
trial design for LSC-targeted therapies,
and elucidation of mechanisms of LSC
resistance to stem-cell-targeted thera-
pies. Notably, the fact that the nonsteroid
anti-inflammatory inhibitor indomethacin
can inhibit b-catenin signaling may facili-
tate trials of this therapeutic approach.
Regardless of the specific target, clinical
trials aimed at LSCs and other cancer
stem cell populations are now beginning
and will elucidate how this approach can
be used to improve outcomes for cancer
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How DNA methylation inhibitors exert their anticancer effects in patients is not well understood. In the latest
issue ofCancer Cell, Tsai et al. (2012) use low-dose drug treatment to induce persistent attenuation of tumor-
igenicity by targeting tumor-initiating cells.There has been a recent surge in the
interest of epigenetics as a causal con-
tributor to cancer, as well as a basis for
alternative approaches to cancer detec-
tion, diagnosis, and therapy. In contrast
to genetic mutations and rearrange-
ments, epigenetic changes, such as
DNA methylation, do not alter the primary
DNA sequence, and are thus considered
more readily reversible. Peter Jones
discovered the first DNA methyltransfer-
ase inhibitors more than 3 decades ago
(Jones and Taylor, 1980), and showed in
this very first paper that 5-azacytidine
(5-aza-CR, AZA) and 5-Aza-20-deoxycyti-
dine (5-aza-CdR, DAC), both display a
very narrow dose range in which they
are able to inducemorphological changes
in 10T1/2 mouse fibroblasts. These drugs
were first synthesized in the 1960s, but
had yielded disappointing results in clin-
ical trials designed to escalate to the
maximum tolerated dose (MTD). Later
trials revealed that the optimal dose of
DAC was considerably lower than previ-
ously thought, with a U-shaped dose-
response curve (Issa et al., 2004; Qin
et al., 2009; Yoo and Jones, 2006). Both
drugs have now been approved by the
FDA for treatment of myelodysplastic
syndrome (MDS).
The complex dose-response relation-
ships of these drugs is attributable tomultiple competing mechanisms, which
are relevant to their efficacy, but which
have also contributed to a poor under-
standing of their mode of action. Once
incorporated into DNA, 5-azacytosine
traps DNA methyltransferases with an
irreversible covalent attachment at the
C-6 position. This has several disparate
consequences. First, the large, covalently
attached protein adduct is thought to
be cytotoxic and mutagenic (Jackson-
Grusby et al., 1997). Second, the incorpo-
rated analog acts as a sink, depleting the
cell of active DNA methyltransferases,
thus inducing secondary loss of DNA
methylation due to the lack of restoration
of DNA methylation following DNA repli-
cation. Third, once DNA methyltrans-
ferases have been fully depleted, then
incorporation of any additional drug
could yield further toxicity associated
with the analog itself, without DNA meth-
yltransferase binding. It has long been
debated whether the anticancer effects
of AZA and DAC are attributable to the
cytotoxicity of the bulky adduct or the
incorporated analog itself, to the reactiva-
tion of epigenetically silenced growth-
suppressing genes by loss of promoter
methylation, or in the case of AZA,
to incorporation of the ribonucleoside
analog into RNA. The slowly emerging
picture is that low-dose AZA or DAC caneffectively deplete DNA methyltrans-
ferases, while high doses induce cell-
cycle arrest and thus may mask replica-
tion-dependent DNA hypomethylation
(Figure 1) (Kelly et al., 2010; Qin et al.,
2009). Compounding these complex
dose-response issues, both AZA and
DAC are unstable in aqueous solution,
potentially hampering their use for poorly
perfused solid tumors. Additional impor-
tant questions remain. For example, the
clinical response of many MDS patients
to DNA methyltransferase inhibitor
therapy is delayed, yet persistent. For
some patients, blast counts continue
to decrease long after termination of
therapy (Issa and Kantarjian, 2009). Such
clinical behavior is clearly different from
that of traditional chemotherapeutic
agents, including the structurally similar
cytarabine. In the latest issue of Cancer
Cell, Baylin, Zahnow and colleagues
explore the anticancer mechanisms of
the AZA and DAC DNA methyltransferase
inhibitors that could account for this de-
layed yet persistent response (Tsai et al.,
2012).
In this report, the authors studied
the effects of these epigenetic inhibitors
at nanomolar concentrations, which ap-
proximate the in vivo concentrations at
optimal dosing, according to pharmaco-
dynamic calculations. Most of thell 10, April 6, 2012 ª2012 Elsevier Inc. 353
